These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 29452419)

  • 1. Temozolomide-associated hypermutation in gliomas.
    Choi S; Yu Y; Grimmer MR; Wahl M; Chang SM; Costello JF
    Neuro Oncol; 2018 Sep; 20(10):1300-1309. PubMed ID: 29452419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
    Yu Y; Villanueva-Meyer J; Grimmer MR; Hilz S; Solomon DA; Choi S; Wahl M; Mazor T; Hong C; Shai A; Phillips JJ; Wainer BH; McDermott M; Haas-Kogan D; Taylor JW; Butowski N; Clarke JL; Berger MS; Molinaro AM; Chang SM; Costello JF; Oberheim Bush NA
    Neuro Oncol; 2021 Nov; 23(11):1872-1884. PubMed ID: 33823014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
    Mathur R; Zhang Y; Grimmer MR; Hong C; Zhang M; Bollam S; Petrecca K; Clarke J; Berger MS; Phillips JJ; Oberheim-Bush NA; Molinaro AM; Chang SM; Costello JF
    Neuro Oncol; 2020 Nov; 22(11):1580-1590. PubMed ID: 32166314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
    van Thuijl HF; Mazor T; Johnson BE; Fouse SD; Aihara K; Hong C; Malmström A; Hallbeck M; Heimans JJ; Kloezeman JJ; Stenmark-Askmalm M; Lamfers ML; Saito N; Aburatani H; Mukasa A; Berger MS; Söderkvist P; Taylor BS; Molinaro AM; Wesseling P; Reijneveld JC; Chang SM; Ylstra B; Costello JF
    Acta Neuropathol; 2015 Apr; 129(4):597-607. PubMed ID: 25724300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
    Sun X; Turcan S
    Cells; 2021 May; 10(5):. PubMed ID: 34067729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
    Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.
    Liu J; Hu S; Jiang H; Cui Y
    Front Immunol; 2024; 15():1369972. PubMed ID: 38690285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
    Wang Q; He Z; Chen Y
    Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.
    Sa JK; Choi SW; Zhao J; Lee Y; Zhang J; Kong DS; Choi JW; Seol HJ; Lee JI; Iavarone A; Rabadan R; Nam DH
    Int J Cancer; 2019 Jun; 144(12):3023-3030. PubMed ID: 30536544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
    Wood MD; Neff T; Nickerson JP; Sayama C; Raslan AM; Ambady P; Corless CL; Nazemi KJ
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):460-463. PubMed ID: 33296093
    [No Abstract]   [Full Text] [Related]  

  • 15. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
    Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
    Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
    Kong DS; Kim HR; Choi YR; Seol HJ; Lee JI; Nam DH
    J Clin Neurosci; 2015 Sep; 22(9):1425-9. PubMed ID: 26138051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
    Johnson BE; Mazor T; Hong C; Barnes M; Aihara K; McLean CY; Fouse SD; Yamamoto S; Ueda H; Tatsuno K; Asthana S; Jalbert LE; Nelson SJ; Bollen AW; Gustafson WC; Charron E; Weiss WA; Smirnov IV; Song JS; Olshen AB; Cha S; Zhao Y; Moore RA; Mungall AJ; Jones SJM; Hirst M; Marra MA; Saito N; Aburatani H; Mukasa A; Berger MS; Chang SM; Taylor BS; Costello JF
    Science; 2014 Jan; 343(6167):189-193. PubMed ID: 24336570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
    Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
    Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.